Financial Analysis: Swedencare AB (publ) (OTCMKTS:SWDCF) versus Zevra Therapeutics (NASDAQ:ZVRA)

Swedencare AB (publ) (OTCMKTS:SWDCF) and Zevra Therapeutics (NASDAQ:ZVRA) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Valuation & Earnings

This table compares Swedencare AB (publ) and Zevra Therapeutics”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Swedencare AB (publ)	N/A	N/A	N/A	N/A	N/A
Zevra Therapeutics	$106.47 million	6.62	$83.23 million	$0.92	12.90

Zevra Therapeutics has higher revenue and earnings than Swedencare AB (publ).

Insider and Institutional Ownership

35.0% of Zevra Therapeutics shares are held by institutional investors. 3.7% of Zevra Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Swedencare AB (publ) and Zevra Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Swedencare AB (publ)	N/A	N/A	N/A
Zevra Therapeutics	42.82%	54.54%	34.15%

Analyst Ratings

This is a summary of recent recommendations and price targets for Swedencare AB (publ) and Zevra Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Swedencare AB (publ)	0	0	0	0	0.00
Zevra Therapeutics	0	1	9	0	2.90

Zevra Therapeutics has a consensus target price of $27.14, suggesting a potential upside of 128.67%. Given Zevra Therapeutics’ stronger consensus rating and higher possible upside, analysts plainly believe Zevra Therapeutics is more favorable than Swedencare AB (publ).

Summary

Zevra Therapeutics beats Swedencare AB (publ) on 9 of the 9 factors compared between the two stocks.

About Swedencare AB (publ)

Swedencare AB (publ), together with its subsidiaries, develops, manufactures, markets, and sells animal healthcare products for cats, dogs, and horses in Sweden, the United Kingdom, Rest of Europe, North America, Asia, and internationally. It offers products and solutions for the pets wellbeing under the Camon name; animal nutritional supplements, treats, and grooming products under the Healthy Breeds name; pet supplements and topical products for various therapeutic areas, such as orthopedics, behavior, dermatology, odontostomatology, algology, gastroenterology, urology, nephrology, and ophthalmology under the Innovet name; and support and solutions for the veterinary community under the Stratford Animal Health name. The company also provides pet health supplements under the NaturVet, VETCLASSICS, and NutriScience name; pet supplements, vitamins, dental care, ear cleaners, pilling agents, and topicals under the Pet MD name; and vet-formulated pet care products under the VetWELL name. In addition, it offers ProDen PlaqueOff powder, a solution for pet oral problems; ProDen PlaqueOff dental bones; ProDen PlaqueOff dental bites, a pet dental product; and Rx Vitamins for Pets. The company distributes its products through veterinarians, pet stores, and online. Swedencare AB (publ) was incorporated in 1993 and is headquartered in Malmö, Sweden.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.